ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2023

Jan 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2023-01-10

Reporting Person: Vakiener Victoria (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-10	Common Stock	D	1764	$0.00	Disposed	15417	Direct
2023-01-10	Common Stock	A	7867	$0.00	Acquired	23284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-10	Common Stock	$33.03	A	4593	Acquired	2033-01-10	Common Stock (4593)	Direct

Footnotes

F1: Correction to previously granted award from 17,181 to 15,417.

F2: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

F3: Includes a total of 15,417 shares underlying restricted stock units, which vest over three years.

F4: Represents options, which will vest in one installment on the first anniversary of the grant date.